Latest: FDA Approves New Biosimilar for Oncology Treatment
Pharmaceutical

Genmab’s epcoritamab combination meets key endpoints in phase 3 lymphoma trial

by PharmaTimes
0 Comments
0 Mins
Promising results support global submissions and priority review by US FDA Promising results support global submissions and priority review by US FDA
Tags:
PharmaTimes
Author

PharmaTimes

Previous Post
Email Disclaimers in Healthcare: A Compliance Essential Hiding in Plain Sight
Next Post
FDA approves AJOVY for paediatric migraine prevention
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago